Amgen’s Uplizna (inebilizumab-cdon) has been approved by the US Food and Drug Administration (FDA) as the first treatment for ...

AstraZeneca (AZ) and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved by the European Commission (EC) to ...

Novartis’ Vanrafia (atrasentan) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat ...

The robots aren’t taking over One commonly held view, thank goodness, is that AI is not going to take over and make us all ...

Virtual publication planning is rapidly evolving with new digital tools, but are you truly optimizing your strategy? Our ...

Medscape, a global leader in infectious disease education, continues its commitment to advancing knowledge in the field. With ...

Takeda UK has announced that the National Institute for Health and Care Excellence (NICE) has recommended Adcetris ...

A report by MedCity ranks London as the number one city in Europe and the third city globally for life sciences. The Global ...

Genmab has announced that the European Commission (EC) has approved Tivdak (tisotumab vedotin) to treat recurrent or ...

Pfizer and Flagship Pioneering have entered into an agreement aimed at discovering potential selective inhibitors for ...

Bristol Myers Squibb (BMS) has announced that its Opdivo (nivolumab) perioperative treatment regimen has been recommended by the European Medicines Agency’s human medicines committee for adults with ...

BeiGene’s Tevimbra (tislelizumab) has been recommended by the European Medicines Agency’s human medicines committee as part of a first-line combination treatment for an aggressive form of lung cancer.